tbuckley/cabot-search huggingface dataset:
WHAT'S IN A NAME?
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of transmural plastic stent on recurrence of pancreatic fluid collection after metal stent removal in disconnected pancreatic duct: a randomized controlled trial
Authors: Radhika Chavan, Zaheer Nabi, Sundeep Lakhtakia, Rajesh Gupta, Basha Jahangeer, Rupjyoti Talukdar, Aniruddha Pratap Singh, Arun Karyampudi, Raghavendra Yarlagadda, Mohan Ramchandani, Rakesh Kalapala, Nitin Jagtap, Manohar Reddy, Manu Tandan, Guduru Venkat Rao, Nageshwar D. Reddy
Journal: Endoscopy (2022)

Background Disconnected pancreatic duct (DPD) after development of walled-off necrosis (WON) predisposes to recurrent (peri)pancreatic fluid collection (PFC). In this randomized controlled trial, we compared plastic stents with no plastic stent after removal of a large-caliber metal stent (LCMS) on incidence of recurrent PFCs in DPD. Methods Consecutive patients with WON who underwent endoscopic ultrasound (EUS)-guided drainage with LCMS between September 2017 and March 2020 were screened for eligibility. At LCMS removal (4 weeks after drainage), patients with DPD were randomized to plastic stent or no stent groups. The primary outcome was incidence of recurrent PFC at 3 months. Secondary outcomes were technical success of plastic stent deployment, adverse events, stent migration, and recurrence of PFC at 6 and 12 months. Results 236 patients with WON underwent EUS-guided drainage using LCMS, and 104 (males 94, median age 34 years (interquartile range [IQR] 26–44.7) with DPD were randomized into stenting (n = 52) and no-stenting (n = 52) groups. Plastic stent deployment was successful in 88.5 %. Migration occurred in 19.2 % at median follow-up of 8 months (IQR 2.5–12). Recurrent PFCs occurred in six patients at 3 months (stent n = 3, no stent n = 3). There was no significant difference in PFC recurrence between the two groups at 3, 6, and 12 months. Reintervention was required in seven patients with recurrent PFCs, with no significant difference between the two groups. Conclusion In patients with WON and DPD, deployment of plastic stents after LCMS removal did not reduce recurrence of PFC.
Cot Deaths
Authors: F. G. Hails
Journal: BMJ (1966)

NDIMWI!L JowuMU adherent to the oesophagus.When the neuroma was dissected away the oesophagus filled out but none the less dilators were passed.The " neuroma " had a cotton ligature in- corporated in it.Since then I have ligated only the distal vagal end, sometimes burying it under a serosal suture to obviate (?) such stump neuromata.The patient has had no recurrence of symptoms since.This case tends to support the view that stump neuromata may by them- selves cause symptoms as suggested in your leader.-Iam, etc.,
Vinblastine, bleomycin, and cis-platinum for the treatment of metastatic malignant melanoma. National Cancer Institute of Canada Melanoma Group.
Journal: Journal of Clinical Oncology (1984)

Sixty-five patients with metastatic melanoma were treated with vinblastine, bleomycin, and cis-diammine dichloroplatinum (VBD). Sixty-four patients were evaluable for response and toxicity. Twelve (19%) of 64 responded. Three patients (5%) achieved a complete response and nine patients (14%) achieved a partial response. Eleven (22%) of 50 previously untreated patients responded. Nine (30%) of 30 women responded while only three (9%) of 34 men responded. All three complete responses were in previously untreated women. Ten (19%) of 52 patients with visceral metastases responded and two (17%) of 12 patients with soft tissue metastases responded. The duration of complete responses was 23, 25, and 32 weeks. The median duration of the partial responses was 20 weeks (range, 12-28 weeks). Major toxicity was encountered. Leukocyte counts less than 1.0 X 10(9)/L were seen in 27% of the patients. There was one sepsis-related death. Platelet counts less than 50 X 10(9)/L were seen in 22% of patients. Mucositis was common. VBD can cause regression of advanced visceral metastatic disease but the low response rate, short duration of response, and major toxicity abrogates most of its utility as initial treatment for metastatic melanoma.
Annals Graphic Medicine - Making the Most of the Post-Call “Day Off”
Authors: Mohamed Taha
Journal: Annals of Internal Medicine (2020)

Web Exclusives7 April 2020Annals Graphic Medicine - Making the Most of the Post-Call “Day Off”FREEMohamed Taha, MDMohamed Taha, MDManama, Bahrain (M.T.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0058 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Manama, Bahrain (M.T.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0058.Author/Illustrator Information: Mohamed Taha, MD (e-mail, moe.n.[email protected]com).This article was published at Annals.org on 24 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 April 2020Volume 172, Issue 7Page: W91-W92KeywordsConflicts of interestDisclosureHealth care ePublished: 24 March 2020 Issue Published: 7 April 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Correspondence
Authors: A. C. Stevenson, J. Bedford, A. G. S. Hill, H. F. H. Hill
Journal: Annals of the Rheumatic Diseases (1976)

Sir, Walker and others (1975) conclude that, 'Our findings do not support those of Stevenson and others (1971) in that there is no significant increase in chromosomal damage in lymphocytes of patients exposed to phenylbutazone (PBZ) or oxyphenbutazone (OPB)'.They express their findings in terms of unstable (Cu) and stable (Cs) chromosomes, but in the following comments only the latter (dicentrics and ring chromo- somes) will be considered.The Liverpool authors include even chromatid gaps and breaks in their Cu scores and these could not have arisen in vivo.They report on findings in lymphocytes of 44 patients with rheumatoid arthritis currently taking PBZ or OPB, and for brevity they will both be called PBZ.The durations of treatment are not stated.In 4178 metaphases from the patients they found 8 dicentrics or rings (D+R) or 0 19%.They had 44
Appropriate technology
Authors: J. Cameron
Journal: BMJ (1984)

<h3>BACKGROUND AND PURPOSE:</h3> Aneurysms arising from the proximal A1 segment of the anterior cerebral artery are rare, and their distinctive configurations often pose technical challenges during endovascular embolization. Herein, we present 11 patients with proximal A1 aneurysms requiring a contralateral approach (via the anterior communicating artery) to coil embolization. <h3>MATERIALS AND METHODS:</h3> From a prospectively collected data repository, we retrieved records of 11 patients consecutively treated for proximal A1 aneurysms between January 2011 and March 2018. In each instance, coil embolization was performed by the contralateral route. Outcomes were analyzed in terms of morphologic features and clinical status. <h3>RESULTS:</h3> Aneurysms in all 11 patients were directed posteriorly and were small (&lt;5 mm). A contralateral approach (via the anterior communicating artery) was used after ipsilateral attempts at aneurysm selection failed in each instance, despite using a variety of microcatheters. Single punctures and single guiding catheters sufficed in 9 patients, but 2 patients required dual punctures and 2 guiding catheters. All endovascular treatments ultimately yielded excellent outcomes. Although 1 symptomatic infarct was manifested in the course of ipsilateral treatment, no morbidity or mortality resulted from the contralateral access. <h3>CONCLUSIONS:</h3> Due to angio-anatomic constraints, a contralateral strategy for coil embolization of proximal A1 aneurysms is acceptable if ipsilateral access is technically prohibitive and the vessels (contralateral A1 and anterior communicating artery) are amenable to the passage of microdevices.
Autoimmune hepatitis in pregnancy: Pearls and pitfalls
Authors: Y. Y. Chung, Michael A. Heneghan
Journal: Hepatology (2022)

Abstract Autoimmune hepatitis (AIH) in pregnancy has many unique considerations. Evidence provided from single center studies with patient level data and nationwide population studies provide valuable insight into this complex situation. Because a planned pregnancy is a safer pregnancy, preconception counseling is a crucial opportunity to optimize care and risk stratify women with AIH. Women with chronic liver disease who receive preconception advice and counseling are more likely to achieve stable liver disease at conception and undergo appropriate variceal surveillance. Loss of biochemical response in pregnancy is associated with adverse outcomes in unstable disease. New onset AIH in pregnancy should be managed with classical treatment regimens. The continued use of immunosuppression in pregnancy, with the exception of mycophenolate mofetil, has not shown to adversely affect the rates of stillbirth or congenital malformation. Previously adopted immunosuppression withdrawal paradigms in pregnancy should no longer be considered advantageous, because remission loss postdelivery is likely (12%–86%). Population studies, report improved outcomes with preterm birth rates falling from 20% to 9%–13% in AIH pregnancies over a 20‐year period. Newer data have also demonstrated an increased risk of gestational diabetes and hypertensive complications in AIH pregnancy, which has implications for management and preeclampsia prevention with aspirin use. This review aims to provide the framework to guide and manage pregnancy in AIH outlining pearls and pitfalls to ensure optimal outcomes for mother, baby and to reduce variation in practice.
Angina pectoris.
Authors: S H Taylor
Journal: BMJ (1971)

Deaths from Tuberculosis SIR,-I have recently conducted an analysis of 71 new cases of tuberculosis diagnosed in a large general hospital over a six-year period.The results confirm some of the comments in your leading article on this subject (22 May, p. 419).In 17 (24%') there was undue delay in making the correct diag- nosis.In 15 an interval of more than three weeks elapsed between hospital admission and diagnosis, and in two tuberculosis was not discovered until necropsy.In these two cases and in seven others, failure to con- sider tuberculosis in the initial differential diagnosis was a major factor in causing this delay.Three of these nine patients had recognized predisposing factors (one was an alcoholic and two were receiving cortico- steroid drugs), and four had extrathoracic tuberculosis.None were immigrants.The necessity of considering tuberculosis in the elderly is confirmed by the case of an 80-year-old woman who presented with weakness, anorexia, abdominal discomfort, and weight loss.Though there was a diffuse bilateral abnormality on chest radiograph, a diagnosis of intra-abdominal malignant disease was made.At necropsy, disseminated miliary tuberculosis was found.These findings and the report of the Research Committee of the British Thoracic and Tuberculosis Association' stress the im- portance of communicating to medical students and postgraduates the continuing need to consider tuberculosis in the differen- tial diagnosis of any unexplained illness, particularly where this occurs in the elderly, in immigrants, and in patients with recog- nized predisposing factors such as diabetes, alcoholism, and corticosteroid therapy.-I
Phenacetin nephropathy.
Authors: L. F. Prescott
Journal: BMJ (1970)

importance of having a manometer or release valve incorporated in the circuit has been stressed.Seed, Shakespeare, and Mul- doon' stated that the inflow pressure should not rise above 20 mm.Hg, a higher pressure usually indicating a blocked cannula.One of their patients suffered from tachycardia and a fall in blood pressure when the insufflation pressure rose above 40mm.Hg for a short time, but recovery occurred immediately on decompression.These authors attributed the hypotension to compression of the vena cava, and suggested that-it was more likely to occur earlier with a tense abdominal wall than with flaccid musculature.Splinting of the diaphragm will also embarrass respiration, and regurgitation of stomach contents may occur.Once the dangers of overdistension are realized they can be easily avoided, but should this occur immediate release of pres- sure and raising the legs should quickly restore normal cardiac and respiratory function.-Iam, etc., HUMPHREY ARTHURE.
Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CMJ, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial Hemodynamic, Endocrine, and Renal Effects of Urocortin in Experimental Heart Failure: Comparison With Normal Sheep.
Journal: Journal of the American College of Cardiology (2003)
P15.13 * THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE: A TOOL TO ASSESS NEUROLOGIC FUNCTION FOR INTEGRATION IN THE RADIOLOGIC ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA
Authors: D. A. Reardon, L. Nayak, L. M. DeAngelis, P. Y. Wen, A. A. Brandes, R. Soffietti, D. M. Peerboom, N. U. Lin, M. Chamberlain, D. Macdonald
Journal: Neuro-Oncology (2014)

BACKGROUND: The Macdonald criteria and RANO criteria define radiologic parameters to classify therapeutic outcome among malignant glioma patients. While both scales specify that clinical status must be incorporated for overall assessment, neither provides specific parameters to do so. Furthermore, both scales prioritize clinical status over radiology in that response requires at least stable clinical status, while clinical deterioration is sufficient to declare progression. We hypothesized that a standardized metric to measure neurologic function will permit better overall response assessment in neuro-oncology. METHODS: An international group of neuro-oncologists convened bi- weekly for the past year to draft the Neurologic Assessment in Neuro-Oncology (NANO) criteria as an objective and quantifiable metric of neurologic function evaluable during a routine office examination. RESULTS: The NANO scale is a quick, clinician-friendly, and quantifiable evaluation of eight relevant neurologic domains based on direct observation/testing conducted during routine office visits. The score defines criteria for domain-specific and overall scores of response, progression, stable disease and not assessed. A given domain will be scored non-evaluable if it cannot be accurately assessed due to pre-existing conditions, co-morbid events, and/or concurrent medications. CONCLUSION: The NANO criteria aims to provide a more detailed and objective measure of neurologic function than currently exists. These criteria are designed to enable a consistent evaluation of neurologic function which will facilitate comparisons across clinical trials and therapeutic interventions. Implementation and validation of these criteria are planned, and future modifications are anticipated for further optimization.
Society Proceedings
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic counselling.
Authors: A E Emery
Journal: BMJ (1975)

With advances in medicine and surgery and the concomitant decline in infectious diseases and nutritional deficiencies, the proportion of morbidity and mortality due to genetic disease has increased. Roughly 1 in 20 children admitted to hospital have a unifactorial or chromosomal disorder. An awareness of genetic disease and the importance of genetic counseling is extending into the general population, so that individuals are requesting genetic counselors on their own. Presently most genetic counseling is provided only after birth, because only then is the need in a particular family recognized. If parents were screened before having children, a much greater proportion of genetic disease could be prevented. The role of the family doctor is important, as he can help and advise or even reinforce advice given by the geneticist and probably enable the parents to understand it better.
Versatile carbon nanoplatforms for cancer treatment and diagnosis: strategies, applications and future perspectives
Authors: Lu Tang, Jing Li, Ting Pan, Yue Yin, Yijun Mei, Qiaqia Xiao, Ruotong Wang, Ziwei Yan, Wei Wang
Journal: Theranostics (2022)

Despite the encouraging breakthroughs in medical development, cancer remains one of the principle causes of death and threatens human health around the world.Conventional treatment strategies often kill cancer cells at the expense of serious adverse effects or great pain, which yet is not able to achieve an effective cure.Therefore, it is urgent to seek for other novel anticancer approaches to improve the survival rate and life quality of cancer patients.During the past decades, nanotechnology has made tremendous progress in cancer therapy due to many advantages such as targeted drug delivery, decreased dosage-related adverse effects and prolonged drug circulation time.In the context of nanomedicine, carbon nanomaterials occupy very significant positions.Owing to their innate outstanding optical, thermal, electronic, and mechanic features, easy functionalization possibility and large surface for drug loading, carbon nanomaterials serve as not only drug carriers, but also multifunctional platforms to combine with diverse treatment and diagnosis modalities against cancer.Therefore, developing more carbon-based nanoplatforms plays a critical role in cancer theranostics and an update overview that summarizes the recent achievement of carbon nanomaterial-mediated anticancer theranostic approaches is of necessity.In this review, five typical and widely investigated carbon nanomaterials including graphene, graphdiyne, fullerene, carbon nanotubes and carbon quantum dots are introduced in detail from the aspect of treatment strategies based on both cancer cells and tumor microenvironment-involved therapeutic targets.Meanwhile, modern diagnostic methods and clinical translatability of carbon nanomaterials will be highlighted as well.
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
Authors: Vadim S Koshkin, Guru P. Sonpavde, Clara Hwang, Begona Mellado, Gareth Tomlinson, Masashi Shimura, Michael Jon Chisamore, Maciej Gil, Yohann Loriot
Journal: Journal of Clinical Oncology (2022)

501 Background: Immune checkpoint inhibitors (ICIs), including pembrolizumab, are among the few treatment options available for platinum-ineligible pts with mUC, but only 25–30% of pts achieve responses with ICIs. FGFR DNA alterations (in 15–20% of mUCs) may contribute to poor responses to ICIs, and FGFR inhibition may sensitize tumors to ICIs by direct action on cancer cells or by altering the tumor microenvironment. In an open-label phase 2 study (NCT04601857), futibatinib, a highly selective, potent, irreversible FGFR1–4 inhibitor with activity in FGFR-deregulated tumors, is being assessed in combination with pembrolizumab in pts with mUC. Here, we report preliminary findings from the safety lead-in phase. Methods: Eligible pts (≥18 y; ECOG PS ≤1) had mUC, were treatment naive in the advanced/metastatic setting, and unfit for, intolerant to, or refusing platinum-based chemotherapy. Prior anti–PD-1/PD-ligand 1/2 or FGFR inhibitor therapy were not permitted. Pts (regardless of FGFR alteration status) were first enrolled in a safety lead-in and received futibatinib 20 mg orally once daily (QD) and pembrolizumab 200 mg IV every 21 d. Dose-limiting toxicities (DLTs) were assessed during the first 21-d treatment cycle. Results: As of September 27, 2021, 6 pts were enrolled in the safety lead-in. Median age was 73.5 y (range, 46–84 y) and 17% (1/6) of pts had an ECOG PS of 1. Median duration of treatment was 48 d (range, 21–141 d) with futibatinib and 35 d (1–114 d) with pembrolizumab. Two pts (33%) remained on treatment at data cutoff. Adverse events (AEs) were reported in all 6 pts; AEs in &gt; 2 pts were diarrhea (83%), hyperphosphatemia (67%), increased aspartate aminotransferase (50%), and pruritis (50%). Grade 3 AEs were reported in 2/6 pts: increased aspartate aminotransferase, maculopapular rash, myositis (17% each). There were no grade 4–5 AEs. AEs led to any study drug discontinuation in 3 pts, dose interruption in 3 pts, and dose modification in 3 pts. All 6 pts were evaluated for DLTs after 1 treatment cycle; no DLTs were reported. Conclusions: Preliminary safety results support tolerability of futibatinib plus pembrolizumab in platinum-ineligible pts with mUC. As no DLTs were observed in the safety lead-in, the recommended dose of futibatinib in combination with pembrolizumab is 20 mg QD. Enrollment in pts with or without FGFR alterations is ongoing to evaluate antitumor activity by FGFR alteration status. Clinical trial information: NCT04601857.